BIOGY Quote, Financials, Valuation and Earnings

BioArctic AB has a net margin of 20.17% compared to BioGaia AB's net margin of -65.15%. BioGaia AB's return on equity of 20.94% beat BioArctic AB's return on equity of 59.48%.

BioGaia AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioArctic AB has an analysts' consensus of -- which suggests that it could fall by --. Given that BioGaia AB has higher upside potential than BioArctic AB, analysts believe BioGaia AB is more attractive than BioArctic AB.

BioGaia AB has a beta of 0.447, which suggesting that the stock is 55.292% less volatile than S&P 500. In comparison BioArctic AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

BioGaia AB has a quarterly dividend of $0.70 per share corresponding to a yield of 6.79%. BioArctic AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioGaia AB pays 180.97% of its earnings as a dividend. BioArctic AB pays out -- of its earnings as a dividend.

BioGaia AB quarterly revenues are $34.3M, which are larger than BioArctic AB quarterly revenues of $14M. BioGaia AB's net income of $6.9M is higher than BioArctic AB's net income of -$9.1M. Notably, BioGaia AB's price-to-earnings ratio is 33.64x while BioArctic AB's PE ratio is 32.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioGaia AB is 7.25x versus 16.71x for BioArctic AB. Usually stocks with elevated PS ratios are considered overvalued.

Camurus AB has a net margin of 20.17% compared to BioGaia AB's net margin of 33.97%. BioGaia AB's return on equity of 20.94% beat Camurus AB's return on equity of 21.63%.

BioGaia AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Camurus AB has an analysts' consensus of -- which suggests that it could fall by --. Given that BioGaia AB has higher upside potential than Camurus AB, analysts believe BioGaia AB is more attractive than Camurus AB.

BioGaia AB has a beta of 0.447, which suggesting that the stock is 55.292% less volatile than S&P 500. In comparison Camurus AB has a beta of 0.933, suggesting its less volatile than the S&P 500 by 6.658%.

BioGaia AB has a quarterly dividend of $0.70 per share corresponding to a yield of 6.79%. Camurus AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioGaia AB pays 180.97% of its earnings as a dividend. Camurus AB pays out -- of its earnings as a dividend.

BioGaia AB quarterly revenues are $34.3M, which are smaller than Camurus AB quarterly revenues of $59.6M. BioGaia AB's net income of $6.9M is lower than Camurus AB's net income of $20.2M. Notably, BioGaia AB's price-to-earnings ratio is 33.64x while Camurus AB's PE ratio is 49.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioGaia AB is 7.25x versus 16.54x for Camurus AB. Usually stocks with elevated PS ratios are considered overvalued.

Hansa Biopharma AB has a net margin of 20.17% compared to BioGaia AB's net margin of -481.29%. BioGaia AB's return on equity of 20.94% beat Hansa Biopharma AB's return on equity of --.

BioGaia AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Hansa Biopharma AB has an analysts' consensus of -- which suggests that it could fall by --. Given that BioGaia AB has higher upside potential than Hansa Biopharma AB, analysts believe BioGaia AB is more attractive than Hansa Biopharma AB.

BioGaia AB has a beta of 0.447, which suggesting that the stock is 55.292% less volatile than S&P 500. In comparison Hansa Biopharma AB has a beta of 0.402, suggesting its less volatile than the S&P 500 by 59.764%.

BioGaia AB has a quarterly dividend of $0.70 per share corresponding to a yield of 6.79%. Hansa Biopharma AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioGaia AB pays 180.97% of its earnings as a dividend. Hansa Biopharma AB pays out -- of its earnings as a dividend.

BioGaia AB quarterly revenues are $34.3M, which are larger than Hansa Biopharma AB quarterly revenues of $3.2M. BioGaia AB's net income of $6.9M is higher than Hansa Biopharma AB's net income of -$15.6M. Notably, BioGaia AB's price-to-earnings ratio is 33.64x while Hansa Biopharma AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioGaia AB is 7.25x versus 12.08x for Hansa Biopharma AB. Usually stocks with elevated PS ratios are considered overvalued.

Orexo AB has a net margin of 20.17% compared to BioGaia AB's net margin of -33.67%. BioGaia AB's return on equity of 20.94% beat Orexo AB's return on equity of -134.37%.

BioGaia AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Orexo AB has an analysts' consensus of -- which suggests that it could fall by --. Given that BioGaia AB has higher upside potential than Orexo AB, analysts believe BioGaia AB is more attractive than Orexo AB.

BioGaia AB has a beta of 0.447, which suggesting that the stock is 55.292% less volatile than S&P 500. In comparison Orexo AB has a beta of 0.861, suggesting its less volatile than the S&P 500 by 13.934%.

BioGaia AB has a quarterly dividend of $0.70 per share corresponding to a yield of 6.79%. Orexo AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioGaia AB pays 180.97% of its earnings as a dividend. Orexo AB pays out -- of its earnings as a dividend.

BioGaia AB quarterly revenues are $34.3M, which are larger than Orexo AB quarterly revenues of $12.2M. BioGaia AB's net income of $6.9M is higher than Orexo AB's net income of -$4.1M. Notably, BioGaia AB's price-to-earnings ratio is 33.64x while Orexo AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioGaia AB is 7.25x versus 1.31x for Orexo AB. Usually stocks with elevated PS ratios are considered overvalued.